All In Biotech

Drug Trial Radar · NCT07588074

Tolerability Comparison of Flarex to Lotemax SM

Tolerability Comparison of Fluorometholone Acetate Ophthalmic Suspension 0.1% (Flarex) to Loteprednol Etabonate Ophthalmic Gel 0.38% (Lotemax SM)

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

May 1, 2021

Primary completion

Jun 30, 2021

Study completion Jun 30, 2021

Sponsor

Lead sponsor
Harrow IncIndustry
Sponsor type
Industry
Collaborators
Eyevance Pharmaceuticals
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects. Each subject received one drop of each product, one in each eye, in a randomized, double-masked design. Comfort, impact on vision, and palpebral conjunctival injection were evaluated at 30 seconds, 5 minutes, and 10 minutes after instillation.

Conditions

  • Ocular Inflammation
  • Keratoconjunctivitis
  • Dry Eye Disease (DED)
  • Post-operative Complications
  • Kerato Conjunctivitis Sicca
  • Dry Eye Syndromes
  • Postoperative Complications

Interventions

  • Fluorometholone Acetate Ophthalmic Suspension 0.1%Drug

    One drop, single instillation, in randomized eye

  • Loteprednol Etabonate Ophthalmic Gel 0.38%Drug

    One drop, single instillation, in randomized eye

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants by Subject-rated Ocular ComfortTime frame: 30 seconds, 5 minutes, and 10 minutes after instillation
  2. Number of Participants by Subject-rated Impact on VisionTime frame: 30 seconds, 5 minutes, and 10 minutes after instillation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Williamson Eye Center

    Baton Rouge, Louisiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.